Jeffrey Hargis, MD
Hematology & Oncology · Louisville, KYNPI 1437122454
Payments from drug & device makers
Across 513 payments — averaging $2491.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Daiichi Sankyo Inc.$360K
- Novartis$231K
- AstraZeneca$174K
- Stemline Therapeutics Inc.$138K
- Gilead$101K
- Radius Health, Inc.$86K
- plus $188K from 13 others
What the payments were for
- Consulting fees$61,50714%
- Speaking & faculty fees$332,32574%
- Travel & lodging$46,91210%
- Food & beverage$7,7332%
- Education$2560%
- Other$1,0980%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Daiichi Sankyo Inc. | 149 | $359,770 |
| Novartis | 24 | $230,791 |
| AstraZeneca(2 entities) | 70 | $174,049 |
| Stemline Therapeutics Inc. | 71 | $138,131 |
| Gilead | 86 | $101,376 |
| Radius Health, Inc. | 14 | $85,666 |
| Merck | 23 | $44,592 |
| Genentech, Inc. | 2 | $32,168 |
| Seagen Inc. | 22 | $29,349 |
| Pfizer | 22 | $27,631 |
| E.r. Squibb & Sons, L.L.C. | 1 | $23,448 |
| Genentech USA, Inc. | 17 | $20,061 |
| Puma Biotechnology, Inc. | 4 | $6,567 |
| Immunomedics, Inc. | 2 | $2,425 |
| Eisai Inc. | 2 | $1,745 |
| Covis Pharma GmbH | 1 | $200 |
| Amgen | 1 | $100 |
| Macrogenics, Inc. | 1 | $98 |
| Lilly USA, LLC | 1 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,278,210 in reported general payments places this provider in the 90th percentile of 143 hematology & oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fentanyl | 33 | $2,860 |
| Anastrozole | 129 | $2,684 |
| Letrozole | 118 | $2,351 |
| Tamoxifen Citrate | 42 | $923 |
| Oxycodone Hcl | 21 | $648 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 11 | $434 |
| Dexamethasone | 28 | $254 |
| Ondansetron Hcl | 29 | $197 |
| Promethazine Hcl | 19 | $97 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Louisville
- Joseph MalyLouisville$7M
- Laila AgrawalLouisville$6.3M
- Jaspreet GrewalLouisville$4.2M
- Rebecca RedmanLouisville$2.1M
- Vivek SharmaLouisville$1.9M
- Rohit KumarLouisville$1.6M
- Goetz KloeckerLouisville$1.2M
- Elizabeth RileyLouisville$746K
- Adam LyeLouisville$706K
- Brian DongLouisville$664K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.